|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF696 |
Gene summary for ZNF696 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF696 | Gene ID | 79943 |
| Gene name | zinc finger protein 696 | |
| Gene Alias | ZNF696 | |
| Cytomap | 8q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9H7X3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79943 | ZNF696 | HCC1_Meng | Human | Liver | HCC | 1.00e-15 | 4.33e-02 | 0.0246 |
| 79943 | ZNF696 | HCC1 | Human | Liver | HCC | 4.68e-05 | 1.31e+00 | 0.5336 |
| 79943 | ZNF696 | HCC2 | Human | Liver | HCC | 1.34e-20 | 2.71e+00 | 0.5341 |
| 79943 | ZNF696 | HCC5 | Human | Liver | HCC | 8.21e-08 | 1.20e+00 | 0.4932 |
| 79943 | ZNF696 | S014 | Human | Liver | HCC | 1.07e-07 | 2.40e-01 | 0.2254 |
| 79943 | ZNF696 | S015 | Human | Liver | HCC | 4.95e-14 | 4.57e-01 | 0.2375 |
| 79943 | ZNF696 | S016 | Human | Liver | HCC | 1.25e-12 | 3.07e-01 | 0.2243 |
| 79943 | ZNF696 | S028 | Human | Liver | HCC | 5.77e-04 | 1.99e-01 | 0.2503 |
| 79943 | ZNF696 | S029 | Human | Liver | HCC | 3.89e-02 | 1.33e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF696 | SNV | Missense_Mutation | novel | c.472N>G | p.Cys158Gly | p.C158G | Q9H7X3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-5M-AAT5-01 | Colorectum | colon adenocarcinoma | Unknown | Unknown | I/II | Unknown | Unknown | Unknown |
| ZNF696 | SNV | Missense_Mutation | novel | c.957N>T | p.Lys319Asn | p.K319N | Q9H7X3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| ZNF696 | SNV | Missense_Mutation | c.812G>A | p.Gly271Asp | p.G271D | Q9H7X3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| ZNF696 | SNV | Missense_Mutation | rs756234415 | c.673N>A | p.Ala225Thr | p.A225T | Q9H7X3 | protein_coding | tolerated(0.57) | benign(0.01) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD |
| ZNF696 | SNV | Missense_Mutation | novel | c.788N>G | p.Asn263Ser | p.N263S | Q9H7X3 | protein_coding | tolerated(0.18) | benign(0.065) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF696 | SNV | Missense_Mutation | novel | c.497C>T | p.Ser166Leu | p.S166L | Q9H7X3 | protein_coding | deleterious(0) | possibly_damaging(0.727) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF696 | SNV | Missense_Mutation | novel | c.610N>G | p.Thr204Ala | p.T204A | Q9H7X3 | protein_coding | deleterious(0.03) | benign(0.431) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| ZNF696 | SNV | Missense_Mutation | novel | c.712N>A | p.Ala238Thr | p.A238T | Q9H7X3 | protein_coding | tolerated(0.26) | benign(0.021) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| ZNF696 | SNV | Missense_Mutation | novel | c.566C>T | p.Ala189Val | p.A189V | Q9H7X3 | protein_coding | deleterious(0.02) | possibly_damaging(0.733) | TCGA-B5-A0JU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF696 | SNV | Missense_Mutation | novel | c.929A>G | p.Glu310Gly | p.E310G | Q9H7X3 | protein_coding | deleterious(0.01) | benign(0.066) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |